Ongoing NCI CER-related activities
Blood and Marrow Transplant (BMT) Clinical
Trials Network (CTN): BMT CTN
was established in October 2001 to conduct large multi-institutional clinical trials.
The trials will address important issues in hematopoietic stem cell transplantation
(HSCT), thereby furthering understanding of the best possible treatment approaches.
Participating CTN investigators collaborate through an organization designed to maintain continuity of operations, to facilitate effective communication and
cooperation among participating transplant centers and with collaborators at the
National Institutes of Health, and to offer trials participation to patients in
all regions of the U.S.
Cancer Intervention and
Surveillance Modeling Network (CISNET): CISNET is a consortium of NCI-sponsored
investigators that use statistical modeling to improve our understanding of cancer
control interventions in prevention, screening, and treatment and their effects
on population trends in incidence and mortality. These models can be used to guide
public health research and priorities.
Contact: Eric J. (Rocky) Feuer, Ph.D.
Cancer Research Network (CRN): The CRN consists of the research programs, enrolled populations,
and data systems of 14 health maintenance organizations nationwide. The overall
goal of the CRN, and the NCI initiative under which it was funded, is to use this
consortium of delivery systems to conduct research on cancer prevention, early detection,
treatment, long-term care, surveillance, and cancer communication and dissemination
and implementation research. A portfolio of research studies encompasses cancer
control topics ranging from modification of behavioral risk factors such as smoking
to cancer care at the end of life.
Contact: Paul Doria-Rose
NCI Community Cancer Centers
Program: The NCI Community Cancer Centers Program (NCCCP) is a three-year
pilot program to test the concept of a national network of community cancer centers
to expand cancer research and deliver the latest, most advanced cancer care to a
greater number of Americans in the communities in which they live. The NCCCP extends
the reach of NCI research into more U.S. states, cities, and towns, including rural
areas and inner cities.
Contact: Frank Blanchard
- SEER-Medicare Health Outcomes
Survey (MHOS) Linkage Project: The Surveillance, Epidemiology, and End Results-Medicare
Health Outcomes Survey (SEER-MHOS) linked database is a research resource designed
to improve our understanding of the
health-related quality of life (HRQOL) of cancer patients and survivors
enrolled in Medicare health plans. SEER-MHOS is sponsored by the National Cancer
Institute (NCI) and the Centers for Medicare & Medicaid
SEER-Medicare Linked Database: The SEER-Medicare data reflect the linkage
of two large population-based sources of data that provide detailed information
about elderly persons with cancer. The data come from the SEER program of cancer
registries that collect clinical, demographic and cause of death information for
persons with cancer and the Medicare claims for covered health care services from
the time of a person's Medicare eligibility until death.
Contact: Elaine Yanisko
Featured Clinical Trials
- Adjuvant Bisphosphonates
for Breast Cancer Trial: Drugs called
bisphosphonates have been shown to slow the progression of bone metastases
and reduce skeletal complications in women with metastatic breast cancer. Bisphosphonates
may also prevent the development of bone metastases in newly diagnosed patients
with no evidence of metastasis. Breast cancer cells stimulate bone cells called
osteoclasts, and these osteoclasts in turn stimulate the growth of breast cancer
cells. A bisphosphonate called clodronate has been shown to interrupt the relationship
between osteoclasts and breast cancer cells in early stage breast cancer. With this
trial, the researchers are comparing clodronate with two newer, more-potent bisphosphonates-zoledronate
National Lung Screening
Trial: Compares two ways of detecting lung cancer: spiral computed tomography
(CT) and standard chest X-ray. Both chest X-rays and spiral CT scans have been used
to find lung cancer early. So far, neither chest X-rays nor spiral CT scans has
been shown to reduce a person's chance of dying from lung cancer. This study will
aim to show if either test is better at reducing deaths from this disease.
Prophylactic Removal of Ovaries to Reduce Cancer Risk Trial: This trial examines
the impact of preventive surgery (Salpingo-oophorectomy to remove the ovaries)
on quality of life, and the consequences of premature menopause in women at high-risk
for ovarian cancer. In addition, there will be genome-wide association studies evaluating
polymorphisms in BRCA mutations to refine the model of risk based on specific BRCA
mutations. This trial is important because women with mutations in the BRCA1 or
BRCA2 genes (genes that normally help to suppress cell growth) face cumulative risks
of developing ovarian cancer of 16-40%. For these women, preventive removal of the
ovaries and fallopian tubes lowers the risk of ovarian and breast cancer, but the
magnitude of these reductions is still uncertain.
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: The PLCO, is
a large-scale clinical trial to determine whether certain cancer screening tests
reduce deaths from prostate, lung, colorectal and ovarian cancer. The underlying
rationale for the trial is that screening for cancer may enable doctors to discover
and treat the disease earlier.
- TAILORx: Testing
Personalized Treatment for Breast Cancer The Trial Assigning IndividuaLized Options
for Treatment (Rx), or TAILORx, is examining whether genes that are frequently associated
with risk of recurrence for women with early-stage breast cancer can be used to
assign patients to the most appropriate and effective treatment. TAILORx seeks to
incorporate a molecular profiling test (a technique that examines many genes simultaneously)
into clinical decision making, and thus spare women unnecessary treatment if chemotherapy
is not likely to be of substantial benefit. TAILORx is one of the first trials to
examine a methodology for personalizing cancer treatment.
Search for other Clinical Trials
that may be CER.